Phosphatidylserine

BC-PS (bovine cortex phosphatidylserine) was the form used in all landmark RCTs of the 1980s and 1990s, including Crook 1991, Cenacchi 1993, and Maggioni 1990. It was derived from bovine or porcine brain tissue, making it DHA-rich at the sn-2 fatty acid position -- closely matching the natural phospholipid composition of the human brain. Following BSE (bovine spongiform encephalopathy / mad cow disease) safety concerns in the mid-1990s, BC-PS was effectively withdrawn from the commercial market. Modern S-PS (soy-derived or sunflower-derived) is produced via phospholipase D-mediated transphosphatidylation of plant lecithin. The serine headgroup is structurally identical, but the acyl chain profile is linoleic acid-dominant rather than DHA-dominant. This matters because the brain preferentially incorporates DHA into PS, and S-PS's remodeling in circulation is incomplete. Studies of S-PS (Kato-Kataoka 2010, Hellhammer 2004, Starks 2008) confirm meaningful benefit, but effect magnitudes tend to be smaller than BC-PS trials. Vakhapova 2010 showed that co-administering S-PS with DHA produced cognitive improvements superior to S-PS alone, suggesting PS + fish oil combination may best approximate BC-PS's composite benefit.

In 2003 the FDA granted a qualified health claim for soy-derived PS and cognitive dysfunction in the elderly (FDA Docket 02P-0413). This is the only qualified health claim ever issued for a nootropic supplement. The 'qualified' designation means the evidence is credible but not conclusive -- the claim must be accompanied by qualifying language ('may reduce', 'very little scientific evidence'). The FDA standard requires 'credible scientific evidence' that a substance may reduce disease risk, a lower bar than drug approval. EFSA reviewed PS cognition claims in 2011 and declined to approve a health claim, stating that insufficient evidence established a cause-and-effect relationship specifically for soy-derived PS and cognitive function maintenance. EFSA's standard for health claims requires consistent evidence of a cause-and-effect relationship, a higher threshold than FDA's qualified claim. The divergence reflects different regulatory philosophies: FDA qualified claims acknowledge uncertainty, EFSA health claims require near-certainty. The EFSA rejection does not negate or contradict the FDA claim -- it reflects a stricter evidentiary bar.

PS modulates the hypothalamic-pituitary-adrenal (HPA) axis via glucocorticoid receptor (GR) dynamics. The proposed mechanism: PS stabilizes GR translocation to the nucleus and enhances GR recycling back to the cytoplasm, sensitizing the feedback inhibition loop that suppresses hypothalamic CRH and pituitary ACTH secretion. With more efficient feedback, ACTH rises less in response to a stressor, and adrenal cortisol output is consequently blunted. Clinical confirmation: Monteleone 1992 showed ACTH and cortisol both suppressed following 400 mg or 800 mg BC-PS administration before a physical stress challenge, with onset within 30-60 minutes. Hellhammer 2004 showed blunted cortisol AUC and peak ACTH after 3 weeks of 400 mg/day S-PS before a standardized Trier Social Stress Test. Starks 2008 showed 39% peak cortisol reduction in athletes at 600 mg/day. The effect is dose-dependent (Monteleone: 400 mg < 800 mg) and appears to have a functional ceiling near 800 mg/day based on available data.

Two RCTs support PS as an ADHD adjunct in children. Manor 2012 (PMID 22810197) randomized 200 children ages 4-14 with ADHD-like symptoms to 200 mg/day S-PS plus omega-3 (DHA/EPA) or placebo for 15 weeks. The PS+omega-3 group showed significantly greater reductions on the Conners' Parent Rating Scale: inattention -14% vs. -1% placebo (p<0.01), hyperactivity/impulsivity -12% vs. -0.6% placebo. Responder rate was 49% in the treatment group vs. 32% placebo. Hirayama 2014 (PMID 24731023) used S-PS alone (200 mg/day, 8 weeks) in 36 Japanese children with ADHD. WISC-III working memory and auditory memory subtests improved significantly; the inattention subscale reached significance but hyperactivity did not. PS is not a replacement for first-line ADHD pharmacotherapy. The Manor trial co-administered omega-3, making it unclear how much benefit is attributable to PS vs. omega-3 alone. Hirayama's PS-only design suggests an independent PS contribution, but the sample was small (n=36). Mechanism: PS supports cholinergic and dopaminergic neurotransmission via membrane scaffolding at synaptic active zones -- pathways directly relevant to ADHD neurobiology.

The dose differs substantially by application. For cognitive benefit in elderly populations, 300 mg/day is the evidence-supported ceiling: Crook 1991 (300 mg), Cenacchi 1993 (300 mg), and Kato-Kataoka 2010 (300 mg) all used this dose. There is no clinical evidence that cognitive benefit increases above 300 mg/day. For cortisol blunting in stressed or athletic populations, the effective range is 400-800 mg/day: Monteleone 1992 used 400 mg and 800 mg (dose-response confirmed), Hellhammer 2004 used 400 mg, Starks 2008 used 600 mg, and Kingsley 2006 used 750 mg. The biohacking community often uses 400-800 mg/day for cognitive purposes by extrapolating from cortisol data -- this is not evidence-supported for the cognitive endpoint. A practical protocol: 300 mg/day if your primary goal is cognitive support; 400-800 mg/day if your primary goal is cortisol blunting under stress or athletic load. These goals can be combined with 600 mg/day as a compromise.

Evidence is consistently weak to null for young healthy adults on cognitive endpoints. Bauschke 2014 found no effect of 400 mg/day PS on working memory in young healthy adults. Dory 1995 found no significant effect on attention or processing speed in university students. The mechanistic explanation: PS primarily compensates for age-related or stress-induced phospholipid depletion and the resulting membrane rigidity, HPA dysregulation, and cholinergic decline. Young adults with intact membrane function, regulated HPA tone, and normal cognition have little compensatory capacity to gain. The exception is cortisol blunting under acute or chronic stress: Hellhammer 2004 showed benefit in healthy volunteers under psychosocial stress, suggesting stressed-but-otherwise-healthy individuals can respond. The clinical picture is clear: PS is not a broad cognitive enhancer. It is a targeted intervention for populations with meaningful phospholipid depletion or elevated HPA tone -- elderly adults, chronically stressed individuals, and athletes with high training load.

PS has a strong safety record in clinical trials. Cenacchi 1993 (n=494, 6 months, 300 mg/day) reported no serious adverse events -- this is the definitive long-term safety trial. Reported side effects are mild and gastrointestinal: nausea, stomach upset, and insomnia (particularly at doses above 300 mg taken in the evening) occur in a minority of users. At 600-800 mg/day, GI discomfort is more commonly reported. No serious drug interactions are established at nutritional doses. Theoretical caution with anticoagulants (PS is membrane-active and could theoretically affect platelet function) but clinical evidence of meaningful bleeding risk is absent. PS externalization is the apoptotic 'eat me' signal in cell biology, but supplemental PS at nutritional doses does not appear to increase apoptotic signaling -- the supplement does not pharmacologically induce apoptosis. The soy-derived form carries standard soy allergen considerations; sunflower-derived PS is the allergen-friendly alternative. Safety rating is favorable within the evidence base; the low safety score in BioHarmony scoring (1.4/5) reflects high safety, not risk -- the scale is inverted (lower score = safer).

PS has two distinct onset timelines depending on the endpoint. For cortisol blunting, the onset is acute: Monteleone 1992 demonstrated measurable ACTH and cortisol suppression within 30-60 minutes of a single 400-800 mg dose. For chronic cortisol attenuation under repeated stress, the full effect develops over 2-3 weeks (Hellhammer 2004: 3-week protocol). For exercise cortisol, Starks 2008 showed significant effect after 10 days of daily dosing. For cognitive function in elderly populations, meaningful improvement requires 4-12 weeks minimum: Crook 1991 showed significant effects at 12 weeks, Kato-Kataoka 2010 at 6 months, and Engel 1992 at 8 weeks. For ADHD symptom improvement, trials used 8-15 weeks. After stopping PS, cortisol blunting dissipates within 1-2 weeks; cognitive improvements persist approximately 4 weeks before regression. There is no permanent effect -- PS is a maintenance supplement.